feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Novo Nordisk Launches Oral Ozempic in Q2

Novo Nordisk Launches Oral Ozempic in Q2

5 Feb

•

Summary

  • Oral Ozempic pill doses approved by FDA are 1.5, 4, and 9 mg.
  • The oral Ozempic will be available in the second quarter of this year.
  • The pill is also approved to lower cardiovascular risk in adults with type 2 diabetes.
Novo Nordisk Launches Oral Ozempic in Q2

Novo Nordisk will introduce oral doses of semaglutide under the brand name Ozempic pill starting in the second quarter of this year. The U.S. Food and Drug Administration has granted approval for 1.5 mg, 4 mg, and 9 mg strengths.

This new oral formulation is designed to enhance patient and healthcare provider recognition of available type 2 diabetes treatments. It aims to address patient inquiries about an oral alternative, noting that Rybelsus tablets have been available since 2019 in different strengths.

Beyond diabetes management, the Ozempic pill is also indicated to reduce the risk of certain cardiovascular conditions in adults with type 2 diabetes who are at high risk. The FDA's approval for these new doses was based on studies for Rybelsus. The company awaits a regulatory decision on a 25 mg dose by the end of 2026.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Novo Nordisk plans to launch the oral Ozempic pill in the second quarter of this year.
The U.S. Food and Drug Administration has approved the oral Ozempic pill in 1.5 milligram, 4 milligram, and 9 milligram doses.
The Ozempic pill is approved for managing type 2 diabetes and also reduces the risk of certain cardiovascular conditions in adults with type 2 diabetes who are at high risk.

Read more news on

Healthside-arrow
trending

Cognizant profit rises 18.7%

trending

HAL shares tumble after AMCA

trending

Bharat Taxi launches in Delhi

trending

JSW Cement Q3 profit rises

trending

Qualcomm stock falls on shortages

trending

MHADA lottery 2026 delayed

trending

Trent share price cautious outlook

trending

Pakistan India T20 boycott

trending

Thunder versus Spurs preview

You may also like

Wegovy Pill Sees Explosive Demand Post-Launch

13 hours ago • 4 reads

article image

Next-Gen Diabetes Drug CagriSema Beats Wegovy in Key Trial

2 Feb • 10 reads

article image

Knock-off Weight Drugs: Deadly Risks Exposed

30 Jan • 62 reads

article image

Weight-Loss Jabs Linked to Severe Pancreatitis Risk

30 Jan • 54 reads

article image

Blindness, Ruptured Colon: Lawsuits Target Ozempic

28 Jan • 58 reads

article image